BT 086

Drug Profile

BT 086

Alternative Names: BT086; IgM concentrate - Biotest

Latest Information Update: 19 Oct 2015

Price : $50

At a glance

  • Originator Biotest AG
  • Class Antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Community-acquired pneumonia

Most Recent Events

  • 01 Apr 2015 Biotest AG completes a phase) II trial in Community acquired pneumonia (Adjunctive therapy) in United Kingdom, Belgium, Spain and Germany (NCT01420744)
  • 01 Aug 2011 Phase-II clinical trials in Community-acquired pneumonia (adjunctive) in Spain (IV) (NCT01420744)
  • 01 Aug 2011 Phase-II clinical trials in Community-acquired pneumonia (adjunctive) in Germany (IV) (NCT01420744)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top